BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma
Neuro-Oncology · 06.04.2023 · 25 (4) · 735-747
DOI: 10.1093/neuonc/noac199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 17.08.2022. Verfasst von Florian Selt und 27 weiteren Autor:innen. Beteiligte Einrichtung: Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Astrocytoma, Brain Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK, Medical Research Council, Brain Tumor Charity.
Abstract (Originalsprache)
Background
Pilocytic astrocytoma (PA) is the most common pediatric brain tumor and a mitogen-activated protein kinase (MAPK)-driven disease. Oncogenic MAPK-signaling drives the majority of cells into oncogene-induced senescence (OIS). While OIS induces resistance to antiproliferative therapies, it represents a potential vulnerability exploitable by senolytic agents.
Methods
We established new patient-derived PA cell lines that preserve molecular features of the primary tumors and can be studied in OIS and proliferation depending on expression or repression of the SV40 large T antigen. We determined expression of anti-apoptotic BCL-2 members in these models and primary PA. Dependence of senescent PA cells on anti-apoptotic BCL-2 members was investigated using a comprehensive set of BH3 mimetics.
Results
Senescent PA cells upregulate BCL-XL upon senescence induction and show dependency on BCL-XL for survival. BH3 mimetics with high affinity for BCL-XL (BCL-XLi) reduce metabolic activity and induce mitochondrial apoptosis in senescent PA cells at nano-molar concentrations. In contrast, BH3 mimetics without BCL-XLi activity, conventional chemotherapy, and MEK inhibitors show no effect.
Conclusions
Our data demonstrate that BCL-XL is critical for survival of senescent PA tumor cells and provides proof-of-principle for the use of clinically available BCL-XL-dependent senolytics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
- Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
- KiTZ Clinical Trial Unit (ZIPO), Department of Pediatric Hematology, Oncology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
- Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), 08028, Barcelona, Spain.
ORCID-Profile: Florian Selt, Romain Sigaud, Stefan Pusch, Cornelis M van Tilburg, Stefan M Pfister, Ina Oehme, Felix Sahm, Till Milde
Förderung
- Cancer Research UK
- Medical Research Council
- Brain Tumor Charity
- The Everest Centre for Low-Grade Pediatric Brain Tumours
- DKTK German Cancer Consortium
- Ramon y Cajal Programme, Ministerio de Economia y Competitividad
- Ministerio de Ciencia, Innovación y Universidades
- Pediatric Brain Tumor Foundation
Zitieren
APA
Selt, F., Sigaud, R., Valinciute, G., Sievers, P., Zaman, J., Alcon, C., Schmid, S., Peterziel, H., Tsai, J. W., Guiho, R., Martínez-Barbera, J. P., Pusch, S., Deng, J., Zhai, Y., van Tilburg, C. M., Schuhman, M. U., El Damaty, A., Bandopadhayay, P., Herold-Mende, C., …, & Milde, T. (2023). BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. Neuro-Oncology, 25(4), 735-747. https://doi.org/10.1093/neuonc/noac199
Vancouver
Selt F, Sigaud R, Valinciute G, Sievers P, Zaman J, Alcon C, et al. BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. Neuro-Oncology. 2023;25(4):735-747. doi:10.1093/neuonc/noac199
BibTeX
@article{Selt2023,
author = {Selt, Florian and Sigaud, Romain and Valinciute, Gintvile and Sievers, Philipp and Zaman, Julia and Alcon, Clara and Schmid, Simone and Peterziel, Heike and Tsai, Jessica W and Guiho, Romain and Martínez-Barbera, Juan Pedro and Pusch, Stefan and Deng, Jing and Zhai, Yifan and van Tilburg, Cornelis M and Schuhman, Martin U and El Damaty, Ahmed and Bandopadhayay, Pratiti and Herold-Mende, Christel and von Deimling, Andreas and Pfister, Stefan M and Montero, Joan and Capper, David and Oehme, Ina and Sahm, Felix and Jones, David T W and Witt, Olaf and Milde, Till},
title = {BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma},
journal = {Neuro-Oncology},
year = {2023},
volume = {25},
number = {4},
pages = {735--747},
doi = {10.1093/neuonc/noac199}
}
EUVIMED